long term side effects of glp-1 drugs 6 Common Taking Medication Struggling with GLP-1 therapy side

Despite Harvard Medical School research published in July 2024 showing diabetes patients prescribed semaglutide faced over four times higher NAION risk (and weight loss patients faced over seven times higher risk) Novo Nordisks current Ozempic and Wegovy labels still mention only generic vision changes without specifically identifying NAION or permanent blindness as known risks

Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, et al

K.et al (2016)

Tirzepatide was FDA-approved for T2D in 2022, and showed impressive weight reductions in subsequent obesity trials

A sensitivity analysis excluding the ITCA trial yielded consistent results (HR (95%CI): 0.83 (0.750.93)

The FDA approved Amneals generic version of AstraZenacas exenatide injection (Byetta)